Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.094
Filter
1.
Invest Ophthalmol Vis Sci ; 65(5): 37, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38780946

ABSTRACT

Purpose: The purpose of this study was to analyze human corneal endothelial cells (HCECs) morphology and ocular biometrics in premature (PM) children with or without retinopathy of prematurity (ROP). Methods: Retrospective data on patient demographics, HCECs status, and ocular biometrics with at least 2 visits between 2016 and 2021 were reviewed. The main outcomes were endothelial cell density (ECD), coefficient of variation (CV), hexagonal cell ratio (HEX), central corneal thickness (CCT), axial length, anterior chamber depth, keratometry, corneal diameter, pupil diameter, and refraction status. Generalized estimating equation was used to evaluate the differences between PM no-ROP and ROP groups. We also analyzed the trend of ECD, CV, HEX, and CCT change with age between groups. Results: The study included 173 PM patients without ROP and 139 patients with ROP. A total of 666 and 544 measurements were recorded in the PM no-ROP and ROP groups, respectively. The ROP group had higher spherical power, myopic spherical equivalent (SE), and steeper steep keratometry (K; P < 0.05). The ROP group had higher CV (P = 0.0144), lower HEX (P = 0.0012) and thicker CCT (P = 0.0035). In the HCECs parameters, the ROP group had slower ECD decrement (P < 0.0001), faster CV decrement (P = 0.0060), and faster HEX increment (P = 0.0001). A difference in corneal morphology changes between the ROP and PM no-ROP groups were prominent in patients with lower gestational age (GA) in the subgroup analysis. Conclusions: Worse HCECs morphology and higher myopic status were initially observed in patients with prior ROP but not in PM patients with no-ROP. ECD and HCECs morphology improved with age, especially in patients with low GA.


Subject(s)
Biometry , Endothelium, Corneal , Gestational Age , Infant, Premature , Retinopathy of Prematurity , Humans , Retinopathy of Prematurity/diagnosis , Retrospective Studies , Male , Female , Infant, Newborn , Endothelium, Corneal/pathology , Refraction, Ocular/physiology , Cell Count , Infant , Child, Preschool , Axial Length, Eye/pathology , Child
2.
Int Immunopharmacol ; 136: 112195, 2024 Jul 30.
Article in English | MEDLINE | ID: mdl-38820965

ABSTRACT

Proper hydration and the clarity of the cornea are maintained through the crucial function of the corneal endothelium. Inflammation of the corneal endothelium, known as endotheliitis, can disrupt endothelial function, resulting in alterations to vision. Corneal endotheliitis is characterised by corneal oedema, the presence of keratic precipitates, inflammation within the anterior chamber, and occasionally, limbal injection, neovascularisation, and the concurrent or overlapping presence of uveitis. The aetiology of this condition is diverse, predominantly viral, but it may also be drug-induced, result from bacterial or fungal infections, be associated with systemic diseases and procedures, or remain idiopathic with no identifiable cause. To date, no standardised protocol for the treatment of this ocular disease exists, and in severe cases, corneal transplantation may be required. A 31-year-old male was transferred to our hospital for the management of corneal endothelial decompensation resulting from corneal endotheliitis. Hormonal therapy and antiviral medications proved ineffective, rendering the patient a candidate for corneal transplantation. As a final measure, treatment with the ROCK inhibitor netarsudil was initiated. The patient demonstrated significant improvement in symptoms, and the inflammation was successfully managed after nine months. In this study, a novel approach employing ROCK inhibitor therapy was utilised for the treatment of corneal endotheliitis, leading to marked recovery during patient follow-up. This case report represents the inaugural application of the ROCK inhibitor netarsudil in managing corneal endothelial decompensation attributed to corneal endotheliitis. These findings suggest that this method warrants consideration as a potential novel treatment option for similar conditions.


Subject(s)
Benzoates , Endothelium, Corneal , Keratitis , beta-Alanine , rho-Associated Kinases , Humans , Adult , Male , Keratitis/drug therapy , Keratitis/diagnosis , rho-Associated Kinases/antagonists & inhibitors , Endothelium, Corneal/pathology , Benzoates/therapeutic use , beta-Alanine/analogs & derivatives , beta-Alanine/therapeutic use , Nitriles/therapeutic use , Corneal Edema/drug therapy , Corneal Edema/etiology , Corneal Edema/diagnosis , Treatment Outcome
3.
BMJ Open Ophthalmol ; 9(1)2024 May 21.
Article in English | MEDLINE | ID: mdl-38772878

ABSTRACT

OBJECTIVE: This study aims to describe the outcome of corneal grafts, both low risk and high risk, after successfully reversed immunological rejection. METHODS: Datasets on reversed rejection episodes in penetrating and endothelial keratoplasties between 2014 and 2019 (n=876) were extracted from the Adverse Immune Signatures and their Prevention in Corneal Transplantation database, which contains the prospectively and consecutively collected corneal transplants from five European centres. Stratified by the preoperatively determined risk status for immunological rejection, the outcome parameters analysed included visual acuity, intraocular pressure, endothelial cell density and central corneal thickness before and after reversed rejection episodes. RESULTS: Fourty-seven (52%) out of a total of 91 identified rejection episodes were successfully reversed and were available for analysis (23 penetrating and 24 endothelial keratoplasties). No statistically significant change was found for any of the parameters studied between the values before and the values 3 months after the rejection episode, irrespective of the preoperative risk status. CONCLUSION: The outcome of corneal grafts that survive immunological rejection may be clinically indistinguishable from the state before immunological rejection, irrespective of graft type and risk status. These findings support clinicians by providing information on prognosis after reversed rejection episodes and by giving patients realistic expectations regarding the outcome.


Subject(s)
Graft Rejection , Visual Acuity , Humans , Graft Rejection/immunology , Graft Rejection/prevention & control , Male , Female , Middle Aged , Aged , Graft Survival , Europe/epidemiology , Keratoplasty, Penetrating , Prospective Studies , Adult , Intraocular Pressure/physiology , Endothelium, Corneal/pathology , Descemet Stripping Endothelial Keratoplasty/methods , Treatment Outcome , Corneal Diseases/surgery , Immunosuppressive Agents/therapeutic use , Risk Factors
4.
Indian J Ophthalmol ; 72(6): 916-918, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38767550

ABSTRACT

Phacoemulsification in hard cataracts is a challenge. The use of dispersive ophthalmic viscosurgical devices (OVDs) to protect the endothelium is a routine step in such scenarios. However, as OVD is transparent, it is difficult to spot within the anterior chamber. Therefore, surgeons may not be aware when the OVD coating of the endothelium disappears during surgery. Consequently, there may be too frequent OVD injections, resulting in a waste of resources. On the contrary, the surgeon may fail to inject OVD at an appropriate time, leading to greater endothelial damage. We propose a novel technique of using an air bubble as a guide that helps in identifying the time when OVD disappears from the anterior chamber, thereby suggesting the surgeon to reinject before proceeding further.


Subject(s)
Air , Phacoemulsification , Viscosupplements , Humans , Phacoemulsification/methods , Viscosupplements/administration & dosage , Hyaluronic Acid/administration & dosage , Endothelium, Corneal/pathology , Anterior Chamber
5.
Sci Rep ; 14(1): 10276, 2024 05 04.
Article in English | MEDLINE | ID: mdl-38704483

ABSTRACT

Fuchs endothelial corneal dystrophy (FECD) is a complex corneal disease characterized by the progressive decline and morphological changes of corneal endothelial cells (CECs) that leads to corneal edema and vision loss. The most common mutation in FECD is an intronic CTG repeat expansion in transcription factor 4 (TCF4) that leads to its altered expression. Corneal endothelial wound healing occurs primarily through cell enlargement and migration, and FECD CECs have been shown to display increased migration speeds. In this study, we aim to determine whether TCF4 can promote cellular migration in FECD CECs. We generated stable CEC lines derived from FECD patients that overexpressed different TCF4 isoforms and investigated epithelial-to-mesenchymal (EMT) expression, morphological analysis and cellular migration speeds. We found that full length TCF4-B isoform overexpression promotes cellular migration in FECD CECs in an EMT-independent manner. RNA-sequencing identified several pathways including the negative regulation of microtubules, with TUBB4A (tubulin beta 4A class IVa) as the top upregulated gene. TUBB4A expression was increased in FECD ex vivo specimens, and there was altered expression of cytoskeleton proteins, tubulin and actin, compared to normal healthy donor ex vivo specimens. Additionally, there was increased acetylation and detyrosination of microtubules in FECD supporting that microtubule stability is altered in FECD and could promote cellular migration. Future studies could be aimed at investigating if targeting the cytoskeleton and microtubules would have therapeutic potential for FECD by promoting cellular migration and regeneration.


Subject(s)
Cell Movement , Endothelium, Corneal , Fuchs' Endothelial Dystrophy , Microtubules , Transcription Factor 4 , Humans , Fuchs' Endothelial Dystrophy/genetics , Fuchs' Endothelial Dystrophy/metabolism , Fuchs' Endothelial Dystrophy/pathology , Cell Movement/genetics , Microtubules/metabolism , Transcription Factor 4/metabolism , Transcription Factor 4/genetics , Endothelium, Corneal/metabolism , Endothelium, Corneal/pathology , Male , Female , Epithelial-Mesenchymal Transition/genetics , Aged , Endothelial Cells/metabolism , Endothelial Cells/pathology , Tubulin/metabolism , Tubulin/genetics , Middle Aged , Protein Isoforms/metabolism , Protein Isoforms/genetics
6.
J Refract Surg ; 40(5): e304-e312, 2024 May.
Article in English | MEDLINE | ID: mdl-38717085

ABSTRACT

PURPOSE: To compare intraoperative performance and early postoperative outcomes following phacoemulsification with two systems using active fluidics and one using gravity-based fluidics. METHODS: In this prospective randomized trial, 200 eyes were randomized to the traditional and Active Sentry groups (n = 80 eyes each) where the Centurion Vision System was used with traditional or Active Sentry (Alcon Laboratories, Inc) hand-pieces, respectively, or the Infinit group (n = 40 eyes) where the Infiniti Vision System (Alcon Laboratories, Inc) was used. Within the traditional and Active Sentry groups, there were two subgroups with low (30 mm Hg) or high (55 mm Hg) intraocular pressure (IOP) used. Outcome measures compared were: cumulative dissipated energy (CDE), percentage change in central corneal thickness (CCT) at 1 day, 1 week, and 1 month, anterior chamber cells at 1 day and 1 week, rate of rise and fall of IOP following occlusion break, corneal endothelial cell density (ECD), and macular thickness 6 months postoperatively. RESULTS: CDE was significantly lower in group II compared to the traditional group (2.96 ± 1.4 vs 4.14 ± 2.2, P = .001). With 30 mm Hg IOP, the Active Sentry group had significantly less percentage change in CCT at 1 week postoperatively compared to the traditional handpiece group (0.01% vs 0.02%, P = .008). Incidence of anterior chamber cells less than grade 2 on day 1 was significantly higher in the Active Sentry group (82.9% vs 52%, P = .03). Percentage change in ECD was significantly lower in the Active Sentry group (-0.957 vs -0.98%, P = .005). Significantly faster rise of IOP to baseline following occlusion break was seen in the Active Sentry group. CONCLUSIONS: The use of Active Sentry handpiece was associated with lower CDE, less postoperative increase in CCT, fewer anterior chamber cells, and faster rise of IOP following occlusion break. [J Refract Surg. 2024;40(5):e304-e312.].


Subject(s)
Intraocular Pressure , Lens Implantation, Intraocular , Phacoemulsification , Visual Acuity , Humans , Prospective Studies , Intraocular Pressure/physiology , Male , Female , Aged , Visual Acuity/physiology , Middle Aged , Endothelium, Corneal/pathology , Cell Count , Postoperative Period , Tomography, Optical Coherence , Hydrodynamics , Anterior Chamber , Intraoperative Period
7.
PLoS Genet ; 20(5): e1011230, 2024 May.
Article in English | MEDLINE | ID: mdl-38713708

ABSTRACT

Fuchs endothelial corneal dystrophy (FECD) is an age-related cause of vision loss, and the most common repeat expansion-mediated disease in humans characterised to date. Up to 80% of European FECD cases have been attributed to expansion of a non-coding CTG repeat element (termed CTG18.1) located within the ubiquitously expressed transcription factor encoding gene, TCF4. The non-coding nature of the repeat and the transcriptomic complexity of TCF4 have made it extremely challenging to experimentally decipher the molecular mechanisms underlying this disease. Here we comprehensively describe CTG18.1 expansion-driven molecular components of disease within primary patient-derived corneal endothelial cells (CECs), generated from a large cohort of individuals with CTG18.1-expanded (Exp+) and CTG 18.1-independent (Exp-) FECD. We employ long-read, short-read, and spatial transcriptomic techniques to interrogate expansion-specific transcriptomic biomarkers. Interrogation of long-read sequencing and alternative splicing analysis of short-read transcriptomic data together reveals the global extent of altered splicing occurring within Exp+ FECD, and unique transcripts associated with CTG18.1-expansions. Similarly, differential gene expression analysis highlights the total transcriptomic consequences of Exp+ FECD within CECs. Furthermore, differential exon usage, pathway enrichment and spatial transcriptomics reveal TCF4 isoform ratio skewing solely in Exp+ FECD with potential downstream functional consequences. Lastly, exome data from 134 Exp- FECD cases identified rare (minor allele frequency <0.005) and potentially deleterious (CADD>15) TCF4 variants in 7/134 FECD Exp- cases, suggesting that TCF4 variants independent of CTG18.1 may increase FECD risk. In summary, our study supports the hypothesis that at least two distinct pathogenic mechanisms, RNA toxicity and TCF4 isoform-specific dysregulation, both underpin the pathophysiology of FECD. We anticipate these data will inform and guide the development of translational interventions for this common triplet-repeat mediated disease.


Subject(s)
Fuchs' Endothelial Dystrophy , Transcription Factor 4 , Trinucleotide Repeat Expansion , Humans , Transcription Factor 4/genetics , Transcription Factor 4/metabolism , Trinucleotide Repeat Expansion/genetics , Fuchs' Endothelial Dystrophy/genetics , Alternative Splicing/genetics , Transcriptome/genetics , Endothelial Cells/metabolism , Endothelium, Corneal/metabolism , Endothelium, Corneal/pathology , Male
8.
Medicine (Baltimore) ; 103(17): e37937, 2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38669379

ABSTRACT

To observe alterations in corneal morphology caused by repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF). Prospective cohort study. Seventy-seven eyes were treated with intravitreal injection of anti-VEGF from June 2021 to March 2023. There were 25 eyes of neovascular age-related macular degeneration (nAMD), 24 eyes of diabetic macular edema (DME), and 28 eyes of retinal vein occlusion (RVO). Aflibercept was used in 37 eyes and Ranibizumab was used in 40 eyes. 3 + PRN was used. Corneal endothelium and corneal thickness were measured using a corneal endothelial microscope. The data related to central corneal thickness, corneal endothelial cell density (ECD), average cell size, coefficient of variation (CV), proportion of hexagonal cells (Hex%) was collected. A comparison was also made between baseline and the dynamic changes of all indexes 1 year following the last injection. It was observed that in comparison to baseline, ECD and Hex% decreased significantly after the 3rd injection of Aflibercept and Ranibizumab. However, ECD did not decrease further and remained at the same level as after the last injection. Hex% and average cell size increased to a certain extent in comparison to the last injection. All the changes were found to be statistically significant (P < .01). After 3 injections, ECD in DME group was markedly lower than that in nAMD and RVO group, but the CV in DME group was higher than that in nAMD as well as RVO groups, and all the differences were statistically significant (P < .05). Following intravitreal anti-VEGF therapy, DME is more likely than other disorders to result in a decrease in ECD. Repeated intravitreal injections of anti-VEGF drugs can reduce the Hex% and ECD to a certain extent. After the last injection, Hex% can progressively recover, and ECD can remain stable without further declining. After injections, ECD in DME group was found to be significantly lower than that in nAMD and RVO groups, but CV in DME group was significantly higher in comparison to the other 2 groups. In patients with macular edema, repeated intravitreal injections of anti-VEGF may have certain effects on corneal morphology. Patients with diabetes mellitus in particular should pay special attention to corneal safety following repeated intravitreal injections if they have significantly reduced ECD at baseline.


Subject(s)
Angiogenesis Inhibitors , Cornea , Intravitreal Injections , Macular Edema , Ranibizumab , Receptors, Vascular Endothelial Growth Factor , Recombinant Fusion Proteins , Vascular Endothelial Growth Factor A , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/adverse effects , Cornea/pathology , Cornea/drug effects , Endothelium, Corneal/drug effects , Endothelium, Corneal/pathology , Macular Degeneration/drug therapy , Macular Edema/drug therapy , Prospective Studies , Ranibizumab/administration & dosage , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/therapeutic use , Retinal Vein Occlusion/drug therapy , Vascular Endothelial Growth Factor A/antagonists & inhibitors
9.
J AAPOS ; 28(3): 103922, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38679138

ABSTRACT

PURPOSE: To report the long-term clinical and endothelial cell count (ECC) results of lensectomy with primary anterior chamber iris claw lens implantation in the eyes of patients ≤18-year-old with ectopia lentis due to Marfan syndrome. METHODS: The medical records of Marfan patients operated on at a single institution from September 2007 to August 2020, with minimum follow-up of 2 years, were reviewed retrospectively. The following data were analyzed: sex, age at surgery, indication for surgery, the position of the lens in relation to the undilated and dilated pupil, corneal endothelial cell counts (ECC), peri- and postoperative complications, pre- and postoperative best-corrected visual acuity. RESULTS: A total of forty-two eyes of 23 patients (12 girls and 11 boys) were included. At least two or more postoperative ECCs were collected from 33 eyes (17 patients). Median age at IOL implantation was 6.1 years (range, 1.8-18). Median overall follow-up time was 6.2 years (range, 2-13.5). Median ECC follow-up time was 6.2 years (range, 2-10). Mean best-corrected visual acuity was 0.71 ± 0.38 logMAR before surgery and 0.02 ± 0.25 logMAR at final follow-up. The mean annual ECC decline was 0.71% ± 2.24. Total cell loss from first to last postoperative measurement was 150 cells ± 394 cells/mm2 (4.81%). Pre- and first postoperative data were available for 17 eyes of 10 patients, with a mean cell loss before and directly after surgery of 269 ± 268 cells (7.94%). Surgery related complications were iris bombé due to blockage of peripheral iridectomy in 3 eyes and claw dislocation due to direct impact trauma in 3 eyes. CONCLUSIONS: In our large, pediatric study cohort, anterior chamber iris claw IOL implantation resulted in an excellent visual outcome and normal endothelial cell loss compared with normative data. Safety measures are recommended to avoid traumatic dislocation of IOLs.


Subject(s)
Anterior Chamber , Ectopia Lentis , Iris , Lens Implantation, Intraocular , Marfan Syndrome , Visual Acuity , Humans , Ectopia Lentis/surgery , Marfan Syndrome/complications , Marfan Syndrome/surgery , Female , Male , Child , Lens Implantation, Intraocular/methods , Retrospective Studies , Visual Acuity/physiology , Child, Preschool , Adolescent , Iris/surgery , Anterior Chamber/pathology , Follow-Up Studies , Infant , Lenses, Intraocular , Postoperative Complications , Endothelium, Corneal/pathology , Cell Count
10.
Eye Contact Lens ; 50(6): 276-278, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38661367

ABSTRACT

PURPOSE: To report a case of corneal endothelial damage caused by alcohol-containing chlorhexidine gluconate (CG-A) and its progression over time. METHODS: This was a case report. RESULTS: A 22-year-old man underwent neurosurgery under general anesthesia. CG-A (1%) was used for disinfection after the application of corneal protection tape. Postoperatively, the patient presented with hyperemia and swelling of the left conjunctiva and was referred to our department. Initial examination revealed left corneal epithelial erosion and corneal edema, which improved on postoperative day 14. The corneal endothelial cell density (ECD) was 3,345 cells/mm 2 on day 14, decreased rapidly to 2,090 cells/mm 2 on day 42, and slowly reduced to 1,122 cells/mm 2 on day 168. Thereafter, no decrease in ECD was observed. CONCLUSIONS: CG formulations can lead to a persistent decrease in ECD over several months, even after improvement of acute corneal edema.


Subject(s)
Chlorhexidine , Endothelium, Corneal , Humans , Male , Chlorhexidine/analogs & derivatives , Chlorhexidine/adverse effects , Young Adult , Endothelium, Corneal/pathology , Endothelium, Corneal/drug effects , Corneal Edema/chemically induced , Corneal Edema/etiology , Corneal Edema/diagnosis , Anti-Infective Agents, Local/adverse effects , Disinfection/methods , Ethanol/adverse effects , Corneal Endothelial Cell Loss/pathology , Corneal Endothelial Cell Loss/diagnosis
11.
Arq Bras Oftalmol ; 87(4): e2023, 2024.
Article in English | MEDLINE | ID: mdl-38656029

ABSTRACT

PURPOSE: To assess the outcomes of deep anterior lamellar keratoplasty or penetrating keratoplasty at the scar and the edema stages. METHODS: Forty-five patients (45 eyes) with keratoconus scar stage (scar group, n=26; penetrating keratoplasty a subgroup, n=7; deep anterior lamellar keratoplasty b subgroup, n=19) and keratoconus edema stage (edema group, n=19; penetrating keratoplasty c subgroup, n=12; deep anterior lamellar keratoplasty d group, n=7) who received penetrating keratoplasty or deep anterior lamellar keratoplasty from 2000 to 2022 were retrospectively studied. At 1, 6, and 12 months after surgery, the best-corrected visual acuity, astigmatism, spherical equivalent, corneal endothelial cell density, and complications were analyzed. RESULTS: The best-corrected visual acuity and average corneal endothelial cell loss rate were not significantly different between the scar and edema groups (p>0.05). At 6 and 12 months after surgery, the astigmatism and spherical equivalent in the scar group were significantly lower than those in the edema group (p<0.05). The spherical equivalent of the deep anterior lamellar keratoplasty b subgroup was lower than that of the penetrating keratoplasty a subgroup in the scar group 6 months after surgery (p<0.05). In the edema group, there was no significant difference in spherical equivalent between subgroups (p>0.05). There were no significant differences in best-corrected visual acuity and astigmatism between subgroups within the two groups (p>0.05). In comparison to the scar group, the edema group experienced more complications. According to a survival analysis, there was no statistically significant difference between the scar group and the edema group regarding the progression of vision. CONCLUSIONS: In terms of the outcomes and prognosis for vision after keratoplasty with edema stage and scar stage, deep anterior lamellar keratoplasty may be as effective as penetrating keratoplasty.


Subject(s)
Cicatrix , Corneal Edema , Keratoconus , Keratoplasty, Penetrating , Visual Acuity , Humans , Keratoconus/surgery , Keratoconus/complications , Keratoconus/physiopathology , Male , Female , Retrospective Studies , Keratoplasty, Penetrating/methods , Adult , Cicatrix/etiology , Treatment Outcome , Corneal Edema/surgery , Corneal Edema/etiology , Young Adult , Corneal Transplantation/methods , Time Factors , Adolescent , Astigmatism/surgery , Astigmatism/physiopathology , Middle Aged , Postoperative Complications , Cell Count , Endothelium, Corneal/pathology , Endothelium, Corneal/surgery
14.
Jpn J Ophthalmol ; 68(3): 225-232, 2024 May.
Article in English | MEDLINE | ID: mdl-38557918

ABSTRACT

PURPOSE: We aimed to compare the efficacy and safety of accelerated contact lens-assisted cross-linking (CA-CXL) with Lotrafilcon B and Comfilcon A lenses in keratoconus (KC) patients with thin corneas. STUDY DESIGN: Retrospective, single-center study. MATERIALS AND METHODS: We retrospectively included 51 eyes of 39 KC patients with corneal thickness <400µm after epithelial scraping (Epi-off), who underwent accelerated CA-CXL treatment with Lotrafilcon B (n=20) and Comfilcon A (n=31). Uncorrected and corrected distance visual acuity (UDVA and CDVA), manifest refraction values, corneal topographic data and endothelial cell density were recorded at preoperative and postoperative 1st, 3rd and 6th month controls. RESULTS: CDVA in the Comfilcon A group was higher than CDVA before surgery at 6 months postoperatively (p<0.001). When the two lenses were compared, CDVA was found to be significantly higher in the Lotrafilcon B group in the preoperative, postoperative 1st month and 3rd month values, but there was no significant difference between the postoperative 6th month values (p=0.028, p=0.018, p=0.044, p=0.181, respectively). The maximum keratometry (Kmax) value at the 6th month after surgery in the Comfilcon A group was significantly lower than in the Lotrafilcon B group (p=0,009). There was no significant difference between the endothelial cell density values between the groups (p=0.623, p=0.609, p=0.794, p=0.458, respectively). There was no significant difference between the progression, regression, and stability rates of the two groups (p=0.714). CONCLUSIONS: Accelerated CA-CXL with Lotrafilcon B and Comfilcon A silicone hydrogel lenses is a safe and effective method to stop progression in patients with thin corneas.


Subject(s)
Collagen , Corneal Topography , Cross-Linking Reagents , Keratoconus , Photochemotherapy , Photosensitizing Agents , Refraction, Ocular , Riboflavin , Visual Acuity , Humans , Keratoconus/diagnosis , Keratoconus/physiopathology , Keratoconus/drug therapy , Keratoconus/therapy , Keratoconus/metabolism , Female , Male , Retrospective Studies , Visual Acuity/physiology , Photosensitizing Agents/therapeutic use , Adult , Riboflavin/therapeutic use , Photochemotherapy/methods , Young Adult , Refraction, Ocular/physiology , Collagen/metabolism , Treatment Outcome , Cornea/pathology , Ultraviolet Rays , Follow-Up Studies , Adolescent , Cell Count , Corneal Stroma/metabolism , Endothelium, Corneal/pathology , Contact Lenses, Hydrophilic , Corneal Cross-Linking
15.
Invest Ophthalmol Vis Sci ; 65(4): 38, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38656280

ABSTRACT

Purpose: Fuchs endothelial corneal dystrophy (FECD) is characterized by Descemet's membrane (DM) abnormalities, namely an increased thickness and a progressive appearance of guttae and fibrillar membranes. The goal of this study was to identify abnormal extracellular matrix (ECM) proteins expressed in FECD DMs and to evaluate their impact on cell adhesion and migration. Methods: Gene expression profiles from in vitro (GSE112039) and ex vivo (GSE74123) healthy and FECD corneal endothelial cells were analyzed to identify deregulated matrisome genes. Healthy and end-stage FECD DMs were fixed and analyzed for guttae size and height. Immunostaining of fibronectin, tenascin-C, osteopontin, and type XIV collagen was performed on ex vivo specimens, as well as on tissue-engineered corneal endothelium reconstructed using healthy and FECD cells. An analysis of ECM protein expression according to guttae and fibrillar membrane was performed using immunofluorescent staining and phase contrast microscopy. Finally, cell adhesion was evaluated on fibronectin, tenascin-C, and osteopontin, and cell migration was studied on fibronectin and tenascin-C. Results: SPP1 (osteopontin), FN1 (fibronectin), and TNC (tenascin-C) genes were upregulated in FECD ex vivo cells, and SSP1 was upregulated in both in vitro and ex vivo FECD conditions. Osteopontin, fibronectin, tenascin-C, and type XIV collagen were expressed in FECD specimens, with differences in their location. Corneal endothelial cell adhesion was not significantly affected by fibronectin or tenascin-C but was decreased by osteopontin. The combination of fibronectin and tenascin-C significantly increased cell migration. Conclusions: This study highlights new abnormal ECM components in FECD, suggests a certain chronology in their deposition, and demonstrates their impact on cell behavior.


Subject(s)
Cell Movement , Endothelium, Corneal , Fibronectins , Fuchs' Endothelial Dystrophy , Osteopontin , Tenascin , Humans , Tenascin/metabolism , Tenascin/genetics , Fibronectins/metabolism , Fibronectins/genetics , Osteopontin/metabolism , Osteopontin/genetics , Fuchs' Endothelial Dystrophy/genetics , Fuchs' Endothelial Dystrophy/metabolism , Endothelium, Corneal/metabolism , Endothelium, Corneal/pathology , Aged , Cell Adhesion , Cells, Cultured , Female , Male , Gene Expression Regulation , Middle Aged , Descemet Membrane/metabolism , Descemet Membrane/pathology
16.
Cornea ; 43(6): 799-803, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38471007

ABSTRACT

PURPOSE: Several techniques have been developed for graft unfolding approaches in Descemet membrane endothelial keratoplasty (DMEK). However, despite these techniques, graft deployment and configuration in eyes with deep anterior chambers remain challenging in some cases. Therefore, in this study, we described a modified technique for DMEK, known as the "double-bubble technique assisted by holding forceps." METHODS: This was a retrospective interventional case series. Patients who underwent DMEK between August 2022 and July 2023, including cases with a history of vitrectomy and scleral fixation of intraocular lens, were enrolled in this study. Two experienced surgeons performed DMEK. In brief, after graft insertion into the anterior chamber, the first bubble with a small volume of air was injected above the graft to open the tight roll, and the graft edge was held using a 25-gauge graft manipulator. The second bubble was injected underneath the graft for fixation, while the graft edge was grasped using forceps during gas injection. The graft was released from the forceps. Best spectacle corrected visual acuity, central corneal thickness, endothelial cell density, and incidence of postoperative complications were measured before and after DMEK. RESULTS: Eleven eyes of 11 patients were included in this study (mean follow-up period, 4.5 ± 4.4 months). Best spectacle corrected visual acuity and central corneal thickness significantly improved postoperatively ( P < 0.001). Rebubbling was required in 2 eyes; no other postoperative complications or primary graft failure were observed. CONCLUSIONS: The present technique enables safe and feasible DMEK surgery in vitrectomized eyes with scleral fixated IOLs and in those with a deep anterior chamber.


Subject(s)
Descemet Stripping Endothelial Keratoplasty , Lens Implantation, Intraocular , Sclera , Visual Acuity , Vitrectomy , Humans , Descemet Stripping Endothelial Keratoplasty/methods , Retrospective Studies , Female , Male , Vitrectomy/methods , Aged , Sclera/surgery , Visual Acuity/physiology , Middle Aged , Lens Implantation, Intraocular/methods , Lenses, Intraocular , Aged, 80 and over , Endothelium, Corneal/pathology , Corneal Diseases/surgery , Follow-Up Studies , Postoperative Complications
18.
J Fr Ophtalmol ; 47(4): 104138, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38484481

ABSTRACT

PURPOSE: To present the clinical, genetic, and histopathological features of the ninth family affected by congenital stromal corneal dystrophy (CSCD) to date. METHODS: Twelve cases of a Spanish family affected by CSCD were analyzed regarding history, visual acuity (VA, decimal scale), an ophthalmologic exam and specular microscopy. Five eyes were treated by deep anterior lamellar keratoplasty (DALK), and thirteen eyes by penetrating keratoplasty (PK). In the two last generations, a genetic study was performed. RESULTS: Most of the patients affected were born with opaque corneas except for three, whose corneas were clear at birth. Biomicroscopy showed a whitish diffuse stromal opacity with an unaltered epithelium, causing poor VA (from hand motions to 0.4). Patients treated with PK presented mean postoperative VA of 0.19±0.20 over a follow-up time of 235.3±101.4months with 38% recurrences. Patients who underwent DALK experienced VA improvement to 0.17±0.11 over a follow-up time of 10.8±2.6months without signs of recurrence. In the latter, the big bubble technique was not achieved, so a manual technique was performed. The genetic study showed heterozygosis for a 1-bp deletion at nucleotide 962 in exon 8 of the decorin gene. CONCLUSIONS: CSCD is a rare entity, which should be treated by DALK whenever possible, obtaining better results than PK. Close monitoring of children of affected individuals is important, because CSCD can progress during the early years of life.


Subject(s)
Corneal Dystrophies, Hereditary , Corneal Transplantation , Keratoconus , Child , Infant, Newborn , Humans , Corneal Transplantation/methods , Corneal Dystrophies, Hereditary/diagnosis , Corneal Dystrophies, Hereditary/genetics , Corneal Dystrophies, Hereditary/pathology , Keratoplasty, Penetrating , Endothelium, Corneal/pathology , Retrospective Studies , Treatment Outcome , Keratoconus/surgery
19.
Am J Ophthalmol ; 262: 1-9, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38307212

ABSTRACT

PURPOSE: To examine corneal graft survival via corneal endothelial cell density (ECD) and corneal endothelial cell loss (ECL) at 5 years post-transplantation in the eyes of patients with and without a history of undergoing glaucoma surgery according to the maturity of the donor corneal endothelial cells. DESIGN: Prospective cohort study. METHODS: This prospective cohort study included 17 patients with glaucoma and 51 patients without glaucoma who underwent Descemet's stripping automated endothelial keratoplasty or penetrating keratoplasty at the Baptist Eye Institute, Kyoto, Japan, between October 2014 and October 2016. Human corneal endothelial cells were cultured from residual peripheral donor cornea tissue, and the maturity of the cells was evaluated by cell surface markers (ie, CD166+, CD44-/dull, CD24-, and CD105-) using fluorescence-activated cell sorting. Kaplan-Meier analysis or the chi-square test was used to assess the rate of successful corneal graft survival post-transplantation. RESULTS: At 36 months postoperatively, the mean ECD and ECL in the glaucoma-bleb eyes were 1197 ± 352 cells/mm2 and 55.5% ± 13.9% in the high-maturity group and 853 ± 430 cells/mm2 and 67.7% ± 18.1% in the low-maturity group, respectively. Kaplan-Meier analysis revealed that at 5 years postoperatively, the overall rate of survival was 45%, that is, 100% in the high-maturity group and 25% in the low-maturity group (P < .05). CONCLUSIONS: The findings in this prospective cohort study revealed that the use of donor corneal grafts containing mature-differentiated corneal endothelial cells could maintain the survival of the transplanted graft for a long-term period, even in patients with a history of undergoing glaucoma surgery.


Subject(s)
Endothelium, Corneal , Glaucoma , Graft Survival , Intraocular Pressure , Tissue Donors , Humans , Graft Survival/physiology , Prospective Studies , Male , Female , Endothelium, Corneal/pathology , Aged , Cell Count , Middle Aged , Intraocular Pressure/physiology , Glaucoma/surgery , Glaucoma/physiopathology , Corneal Endothelial Cell Loss/diagnosis , Keratoplasty, Penetrating , Descemet Stripping Endothelial Keratoplasty , Follow-Up Studies , Flow Cytometry , Aged, 80 and over , Visual Acuity/physiology
20.
Am J Ophthalmol ; 262: 10-18, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38316200

ABSTRACT

PURPOSE: To evaluate the association between the endothelial cell density (ECD) and central corneal thickness (CCT) in medium, short, and long eyes of preoperative Han Chinese cataract patients. DESIGN: Retrospective cross-sectional study. METHODS: We consecutively enrolled 410 eyes, namely, 50 short eyes (axial length [AL]<22.0 mm), 150 medium eyes (22.0≤AL<24.0 mm), 120 medium-long eyes (24.0≤AL<26.0 mm), and 90 long eyes (AL≥26.0 mm), of 410 adult patients scheduled for cataract surgery. The ECD and CCT were determined preoperatively with a noncontact specular microscope. The association between the CCT and ECD was identified by using a multivariable regression analysis. A thin cornea was defined as having a CCT less than 500 µm. RESULTS: After adjusting for age, the presence of arterial hypertension, the presence of diabetes mellitus, intraocular pressure, and AL, a positive association between the CCT and ECD was identified in short eyes (linear regression coefficient [B]=3.40; standardized B [ß]=0.52; P = .03), medium eyes (B = 2.33; ß=0.28; P = .002), medium-long eyes (B = 1.84; ß=0.25; P = .02), and long eyes (B = 2.69; ß=0.41; P = .04). In the total group, the multivariable logistic analysis showed a significant link between the presence of a thin cornea and a lower ECD (odds ratio [OR]=0.80 per 100 cells/mm2 increase; P = .001). CONCLUSIONS: For cataract patients of Han ethnicity, a significant association between a thin CCT and a lower ECD was shown across the AL spectrum and was most prominent in short eyes. Eyes with a thin cornea are more likely to have a lower ECD.


Subject(s)
Asian People , Cataract , Cornea , Endothelium, Corneal , Humans , Male , Female , Retrospective Studies , Cross-Sectional Studies , Aged , Cell Count , Endothelium, Corneal/pathology , Middle Aged , Cornea/pathology , Cataract/ethnology , Cataract/pathology , Asian People/ethnology , China/epidemiology , Axial Length, Eye/pathology , Corneal Pachymetry , Aged, 80 and over , Intraocular Pressure/physiology , East Asian People
SELECTION OF CITATIONS
SEARCH DETAIL
...